Etonogestrel
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Etonogestrel: From Contraception to Amenorrhea
One-Sentence Summary
Etonogestrel is a synthetic progestin best known as the active hormone in long-acting subdermal contraceptive implants (e.g. Nexplanon). The TxGNN model predicts it may be effective for Amenorrhea, but this direction is currently supported by 0 clinical trials and 0 publications — the prediction rests on knowledge-graph inference alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Contraception (subdermal progestin implant) — not documented in this Evidence Pack; based on established pharmacological knowledge of etonogestrel |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, source-verified mechanism-of-action data is not available in this Evidence Pack (original_moa is flagged as a data gap). Based on the drug’s known pharmacology, etonogestrel is a progesterone-receptor agonist: it suppresses ovulation and induces endometrial atrophy. This same mechanism is why amenorrhea is a well-recognised side effect of etonogestrel implants in contraceptive use.
The TxGNN prediction appears to be drawing on this same mechanistic pathway, but in reverse — proposing etonogestrel as a deliberate treatment for amenorrhea-adjacent conditions (e.g. therapeutic induction of amenorrhea for heavy menstrual bleeding or endometriosis-related pain, a strategy with precedent among other progestins). However, this Evidence Pack contains no clinical trials or literature that test etonogestrel specifically for treating amenorrhea, so the mechanistic plausibility cannot yet be distinguished from a knowledge-graph artifact.
It is also worth noting that 7 of the other 9 top-ranked candidates in this pack are benign breast conditions (fibrocystic disease, adenosis, mammary dysplasia, etc.) with similarly zero trial/literature support — suggesting the model may be clustering around hormone-adjacent disease nodes in the graph rather than surfacing a specific, well-differentiated pharmacological signal for amenorrhea itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Etonogestrel is currently not registered with SAHPRA (0 licenses on file; market status: Not marketed). No approved South African product information is available to reference for indication wording, dosage form, or Essential Medicines List (EML) status.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: this Evidence Pack flags TFDA/product-label warnings and contraindications as a Blocking data gap — this alone would prevent progression to a formal safety review even if clinical evidence for the new indication were stronger.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (amenorrhea) is supported only by the TxGNN knowledge-graph score (L5 — model prediction only, no supporting studies), with zero clinical trials or literature identified. Combined with the absence of any SAHPRA registration and a Blocking data gap on safety warnings/contraindications, there is insufficient evidence to advance this candidate past a research question.
To proceed, the following is needed:
- Verified mechanism-of-action and product-label data (SAHPRA/manufacturer PI) to resolve the Blocking data gap (DG001)
- Confirmed original indication and regulatory history for etonogestrel outside South Africa, for comparison
- Preclinical or observational evidence specifically evaluating etonogestrel for amenorrhea treatment (as opposed to amenorrhea as a contraceptive side effect)
- If pursued further, consider whether rank-8 candidate (lactation disease, L3 — 2 completed trials) is a more evidence-ready starting point, though those trials assessed breastfeeding compatibility rather than therapeutic efficacy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.